Research reportClonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects
Introduction
A number of recent studies implicate glutamate (Glu) as a transmitter in nociceptive pathways in the spinal cord and suggest that hyperactivation of NMDA (N-methyl-d-aspartate) Glu receptors on small interneurons (wide dynamic range neurons) in the dorsal horn of the spinal cord is crucial for the mediation of certain types of chronic pain, including neuropathic pain 1, 2, 17, 26, 32. The neuropathic pain syndrome consists of chronic pain, dysesthesia, hyperalgesia and allodynia [12]. It is largely unresponsive to analgesic medications, including opiates. However, both animal and preliminary human studies have shown NMDA antagonists to be beneficial in alleviating symptoms of neuropathic pain 4, 6, 7, 9, 17, 20, 21, 26.
A significant obstacle to the therapeutic use of NMDA antagonists in the management of chronic pain is their potentially serious side effects; they are known to induce psychotomimetic reactions in adult humans 8, 10, 18, 25and induce behavioral disturbances such as learning and memory impairments, sensorimotor disturbances, stereotypical behaviors, and hyperactivity 26, 27, 31and pathomorphological changes in neurons of the posterior cingulate/retrosplenial (PC/RS) cortex of the adult rat 3, 13, 22, 23. On a more optimistic note, it has been found that several classes of drugs, when administered together with NMDA antagonists, can prevent their neurotoxic side effects 23, 24. Of particular interest is the recent finding [11]that alpha-2 adrenergic agonists, including clonidine, can prevent the neurotoxic side effects of NMDA antagonists. Relevance of this finding to the management of chronic pain is suggested by the following observations: (1) Transdermal clonidine may confer some therapeutic benefit in the management of diabetic neuropathic pain [33]; (2) Intrathecal administration of either clonidine or the potent NMDA antagonist, MK-801, to rats reduces the tactile hyperesthesia associated with spinal nerve ligation, and intrathecal co-application of clonidine plus MK-801 provides a greater anti-hyperesthetic effect than either agent by itself [19].
To explore further the potential advantage of combined treatment with an NMDA antagonist and alpha-2 adrenergic agonist, we undertook the present experiments in which clonidine and MK-801 were administered systemically to rats and tested for their ability, individually or in combination, to reduce the hyperesthetic response to thermal stimulation in a rat sciatic nerve ligation model of neuropathic pain [5]. In addition, a separate set of experiments was conducted on normal unoperated rats to assess the effects of clonidine on increased locomotor activity induced by MK-801.
Section snippets
Chemicals and animals
Experiments were performed on adult female Sprague–Dawley rats (weight 290–320 g). The noncompetitive NMDA antagonist MK-801 (dizocilpine) was purchased from Research Biochemicals, Natick, MA, and clonidine, an alpha-2 adrenergic agonist, from Sigma Chemical, St. Louis, MO.
Sciatic nerve ligation
In order to induce the hyperesthetic state in rats, a loose ligation of the sciatic nerve was performed [5]. Rats were maintained in a surgical plane of anesthesia with isoflurane (delivered by vaporizer through a nose cone)
General health of the operated animals
The animals subjected to sciatic nerve ligation maintained a normal weight following surgery and had a normal appearance except that they demonstrated a definite limp and the toes of the hind paw on the operated side were held in a ventroflexed posture. In addition, the affected hind paw was held close to the body reflecting an apparent reluctance to place it on the floor. As previously described by Bennett and Xie [5], a significant degree of hyperesthesia was elicitable approximately 7–10
Discussion
Here we show that an NMDA antagonist, MK-801, at a dose (0.05 mg/kg s.c.) that induces mild hyperactivity but is subthreshold for producing cerebrocortical neurotoxic changes, relieves the hyperalgesic state associated with sciatic nerve ligation. However, the analgesic effect at this dose was very transient, and no analgesic effect was observed at a lower dose (0.025 mg/kg s.c.) of MK-801. Clonidine, at a dose (0.05 mg/kg s.c.) that prevents the cerebrocortical neurotoxic effects of MK-801 [11]
Acknowledgements
This work was partially supported by NIH grants AG 11355, DA 05072 and RSA MH38894 (JWO). Portions of the present work were presented at the 1996 Society for Neuroscience Meetings.
References (33)
- et al.
Excitatory amino acid receptors and nociceptive neurotransmission in rat spinal cord
Pain
(1990) - et al.
Response of chronic neuropathic pain syndromes to ketamine: a preliminary study
Pain
(1994) - et al.
A peripheral mononeuropathy in rat produces disorders of pain sensation like those seen in man
Pain
(1988) - et al.
MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy
Brain Res.
(1991) - et al.
Differential effects of excitatory amino acid antagonists on dorsal horn nociceptive neurones in the rat
Brain Res.
(1990) - et al.
The clinically tested N-methyl-d-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy
Neurosci. Lett.
(1995) - et al.
A2 adrenergic agonists prevent NMDA antagonist neurotoxicity
Neuropsychopharmacology
(1995) - et al.
Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-d-aspartate (NMDA) antagonist MK(+)801 (Dizocilpine Maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex
Exp. Neurol.
(1993) - et al.
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia
Pain
(1988) - et al.
The NMDA-receptor antagonist CPP abolishes neurogenic `wind-up pain' after intrathecal administration in humans
Pain
(1992)
Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy
Brain Res.
NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins and research tools for studying schizophrenia
Neuropsychopharmacology
Modulation of neuropathic pain behavior in rats by spinal disinhibition and NMDA receptor blockade of injury discharge
Pain
Alpha-2 adrenoceptor-mediated inhibition of capsaicin-evoked release of glutamate from rat spinal dorsal horn slices
Neurosci. Lett.
Spinal pharmacology of thermal hyperesthesia induced by constriction injury of sciatic nerve. Excitatory amino acid antagonists
Pain
Transdermal clonidine vs. placebo in painful diabetic neuropathy
Pain
Cited by (52)
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
2022, Journal of the Neurological SciencesCitation Excerpt :The logic in utilizing clonidine, an alpha-2-adrenergic agonist, stems from the hypothesis that ketamine hyperactivates the cholinergic pathway from the basal forebrain and the glutamatergic pathway from the thalamus. The hyperactivity and convergence of these two pathways on corticolimbic neurons may lead to stimulated behavioral effects; thus, blocking the cholinergic pathway may decrease stimulation of downstream corticolimbic neurons (164–166). Transient cognitive impairment can occur with subanesthetic doses of ketamine given over 40 minutes to 120 minutes at doses of 0.4 to 0.8mg/kg in healthy volunteers.